Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, 5th Floor, Tower Wing, Great Maze Pond, Guy's Hospital, London SE1 9RT, UK.
Adv Exp Med Biol. 2013;735:247-55. doi: 10.1007/978-1-4614-4118-2_17.
Complement activation occurs in at least two phases when an organ is transplanted into a naive recipient: during reperfusion with recipient blood particularly when the donor organ has undergone a significant period of ischaemia and then during acute rejection once the recipient immune system has recognised the donor tissue as non-self. Both of these reactions are most obvious in the extravascular compartment of the transplanted organ and involve local synthesis of some of the key complement components as well as loss of controls that limit the activation of the pivotal component C3. In contrast, sensitised individuals with pre-existing circulating antibodies have an immediate reaction against the transplant organ that is also complement dependent but is enacted in the intravascular space. All three types of injury (ischaemia-reperfusion, acute rejection, hyperacute rejection) have a critical effect on transplant outcome. Here we discuss therapeutic strategies that are designed to overcome the impact of these factors at the start of transplantation with the aim of improving long-term transplant outcomes. These include the concept of treating the donor organ with modified therapeutic regulators that are engineered to be retained by the donor organ after transplantation and prevent inflammatory injury during the critical early period. By targeting the donor organ with anchored therapeutic proteins, the systemic functions of complement including host defence remain intact. The control of complement activation during the first stages of transplantation, including the possibility that this will reduce the capacity of the graft for stimulating the adaptive immune system, offers an important prospect for increasing the longevity of the transplant and offsetting demand on the limited supply of donor organs. It also provides a model in which the benefits and indications for localised therapy to maximise therapeutic efficiency and minimise the systemic disturbance may be instructive in other complement-related disorders.
补体激活至少发生在两个阶段,当一个器官被移植到一个幼稚的受者中:在与受者血液再灌注期间,特别是当供体器官经历了显著的缺血期,然后在急性排斥期间,一旦受者免疫系统将供体组织识别为非自身。这两种反应在移植器官的血管外腔室中最为明显,涉及一些关键补体成分的局部合成,以及限制激活关键成分 C3 的控制的丧失。相比之下,具有预先存在的循环抗体的致敏个体对移植器官有立即的反应,这种反应也是补体依赖性的,但发生在血管内空间。所有三种损伤(缺血再灌注、急性排斥、超急性排斥)对移植结果都有至关重要的影响。在这里,我们讨论了旨在克服移植开始时这些因素影响的治疗策略,目的是改善长期移植结果。这些策略包括用经过修饰的治疗调节剂治疗供体器官的概念,这些调节剂在移植后被供体器官保留,并在关键的早期预防炎症损伤。通过将锚定治疗蛋白靶向供体器官,可以保留补体的系统功能,包括宿主防御功能。在移植的早期阶段控制补体激活,包括这可能会降低移植物刺激适应性免疫系统的能力,为增加移植的寿命和弥补有限的供体器官供应提供了一个重要的前景。它还提供了一个模型,其中局部治疗的益处和适应症可以最大限度地提高治疗效率并最小化系统干扰,这在其他与补体相关的疾病中可能具有启示性。